Human ALDH comprise 19 subfamilies in which ALDH1A1, ALDH1A3, ALDH3A1,
ALDH5A1, ALDH7A1, and ALDH18A1 are implicated in CSC. Studies have shown that …

Aldehyde dehydrogenases (ALDHs) are a family of detoxifying enzymes often upregulated
in cancer cells and associated with therapeutic resistance. In humans, the ALDH family …

Patients with high ALDH1A3-expressing glioblastoma (ALDH1A3 hi GBM) show limited
benefit from postoperative chemoradiotherapy. Understanding the mechanisms underlying …

Solid tumors can be divided into benign solid tumors and solid malignant tumors in the
academic community, among which malignant solid tumors are called cancers. Cancer is …

Elevated aldehyde dehydrogenase (ALDH) activity correlates with poor outcome for many
solid tumors as ALDHs may regulate cell proliferation and chemoresistance of cancer stem …

Therapy resistance is a major hurdle to the treatment of human malignant tumors. Both DNA
damage repair and stem-like properties contribute to chemoresistance and radioresistance …

Simple Summary For the small subset of pancreatic ductal adenocarcinoma (PDAC) patients
with loss-of-function mutations to BRCA1/2 or PALB2, both first-line and maintenance …

Simple Summary The DNA damage response (DDR) is frequently altered in ovarian cancer
(OC), which can be exploited for therapeutic purposes. Moreover, targeting DDR signaling …

Nanomaterials as radioenhancer have been widely studied, which exhibits huge
advantages in tumor radiotherapy. However, DNA damage repair in tumor cells leads to …

Modern cancer chemotherapy originated in the 1940s, and since then, many
chemotherapeutic agents have been developed. However, most of these agents show …